ERBB2 and breast carcinoma: Particularly, in vitro assays proved that the HER2 hCAR-T with the co-stimulatory domain 41BBζ exhibited high levels of specific cytotoxicity directed at multiple tumor targets that express high and low antigen levels, like the HER2-low breast cancer cell line MDA-MB-231.